Visiongain has published a new report entitled Biobanking 2022-2032. It includes profiles of Biobanking and Forecasts Market Segment by Type (Standalone, Partnership) Market Segment by Application, (Regenerative Medicine, Life Science Research, Clinical Research) Market Segment by Ownership, (National/ Regional, Universities, Non-Profit, Private) Market Segment by Sample Type, (Blood Products, Human Tissues, Nucleic Acids, Cell Lines, Biological Fluids, Other Samples) Market Segment by Product and Service, (Equipment, Consumables, Services, Software) plus COVID-19 Impact Analysis and Recovery Pattern Analysis (“V”-shaped, “W”-shaped, “U”-shaped, “L”-shaped), Profiles of Leading Companies, Region and Country.
The global biobanking market was valued at US$56,955 million in 2021 and is projected to grow at a CAGR of 4.67% during the forecast period 2022-2032.
Growing Opportunities for IT Companies in the Biobanking Market
Biobanks work hard to allocate financing to IT companies since it is suited for all biobanking activities, from subject recruitment to the publication of research results. Top investment objectives include specimen management as well as an accessible channel for organizations and individuals. A growing area of interest is the use of common standards to provide access to clinical and experimental databases. If ontologies are correctly standardized, this enables thorough example annotation. For instance, ongoing and…
